Celldex Therapeutics, Inc. Marketable Securities (Current)
Celldex Therapeutics, Inc. (CLDX) had Marketable Securities (Current) of $670.13 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-06
- 2026-06-30: Marketable Securities, Current $670.13M.
- 2026-03-31: Marketable Securities, Current $415.73M.
- 2025-12-31: Marketable Securities, Current $489.70M.
- 2025-09-30: Marketable Securities, Current $547.19M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $670.13M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $415.73M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $489.70M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $547.19M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $607.29M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $656.15M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $696.92M 10-K · filed 2026-02-25 |
| 2024-09-30 | $719.60M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $759.58M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $708.77M 10-Q · filed 2024-05-06 |
| 2023-12-31 | $388.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $214.21M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $224.47M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $224.26M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $275.52M 10-K · filed 2024-02-26 |
| 2022-09-30 | $304.89M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $328.42M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $355.18M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $369.11M 10-K · filed 2023-02-28 |
| 2021-09-30 | $350.90M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $120.59M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $106.77M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $150.59M 10-K · filed 2022-02-28 |
| 2020-09-30 | $181.44M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $138.89M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $31.00M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $53.15M 10-K · filed 2021-03-29 |
| 2019-09-30 | $56.33M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $61.60M 10-Q · filed 2019-08-07 |
| 2018-12-31 | $69.71M 10-K · filed 2020-03-26 |
| 2012-03-31 | $69.37M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $41.41M 10-Q · filed 2012-05-04 |
| 2011-09-30 | $49.68M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $60.41M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $39.81M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |